KCT0003564已完成未知
A Phase 2 Study to Evaluate the Safety and Efficacy of nab®-Paclitaxel plus Gemcitabine in Korean Patients with Metastatic and Advanced Pancreatic Ductal Adenocarcinoma
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 111
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 80(Year)（—）
- 性别
- All
入选标准
- •A subject will be eligible for inclusion in this study only if all of the following criteria are met:
- •1.Histologically or cytologically confirmed metastatic (cohort 1) or locally advanced unresectable (cohort 2) pancreatic ductal adenocarcinoma (Islet cell neoplasms or neuroendocrine carcinomas are excluded)
- •2.Locally advanced unresectable pancreatic cancer according to radiographic criteria (CT or MRI scans) or exploration:
- •(1) Superior mesenteric vein and portal vein: occlusion, thrombosis, or encasement extending several centimeters
- •(2) Superior mesenteric artery: tumor abutment > 180 degrees or thrombosis of artery
- •(3) Celiac axis: abutment or encasement of the celiac axis
- •(4) Lymph nodes: involvement
- •3. = 19 years of age at the time of signing the informed consent document
- •4.ECOG 0-1
- •5.At least one measurable lesion according to Recist v1.1
- •6.No prior palliative chemotherapy for the treatment of metastatic or locally advanced pancreatic cancer (Prior treatment with 5-FU or gemcitabine administered as a radiation sensitizer in the adjuvant setting is allowed if the treatment had been received at least 6 months before enroll).
- •7.Adequate BM function: ANC =1.5 × 109/L; Platelet count =100,000/mm2 (100 × 109/L); Hb (Hb) =9 g/dL.
- •8.Adequate liver and renal function (obtained =14 days prior to enroll): AST (SGOT), ALT (SGPT) =2.5 × upper limit of normal range (ULN), unless liver metastases are clearly present, then =5 × ULN is allowed; ALP(Alkaline phosphatase) =2.5 ULN;
- •Total bilirubin 1.5 = ULN; Serum creatinine within normal limits or calculated clearance = 60 mL/min/1.73 m2
- •9.Albumin level = 3 g/dl
- •10.Subjects should be asymptomatic for jaundice prior to Cycle 1 Day 1
- •11.Subject with signed the Informed Consent Form (ICF) prior to participation in any study-related activities.
- •12.Female of childbearing potential (FCBP) (defined as a sexually mature woman who (1) has not undergone hysterectomy [the surgical removal of the uterus] or bilateral oophorectomy [the surgical removal of both ovaries] or (2) has not been naturally postmenopausal for at least 24 consecutive months [ie, has had menses at any time during the preceding 24 consecutive months]) must:
- •a.Either commit to true abstinence or agree to the use of 2 physician-approved contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on IP; and for 3 months following the last dose of IP; and
- •b.Has a negative serum pregnancy test (ß-hCG) result at screening
- •13.Male subjects must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions, and for 6 months following IP discontinuation, even if he has undergone a successful vasectomy
- •14.Subject able to adhere to the study visit schedule and other protocol requirements.
排除标准
- •A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- •1.Subject has known symptomatic brain metastases. (Subjects with adequately treated brain or CNS metastases are and have been stable may be included)
- •2.Any metastasis for patients with locally advanced disease (cohort 2)
- •3.History of malignancy in the last 5 years.
- •4.Breast-feeding or pregnant female
- •5.Patients with plastic biliary stent (Metal biliary stents are allowed.)
- •6.Subject has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
- •7.Subject with known history of HIV or know history of active hepatitis B, or hepatitis C and are currently serologically positive with evidence of active chronic active hepatitis.
- •8.Subject has undergone major surgery within 4 weeks prior to Cycle 1 Day 1 of treatment in this study.
- •9.Subject who experienced a recent myocardial infarction, including severe/unstable angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension, clinically significant cardiac dysrhythmia or clinically significant electrocardiogram (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and cerebrovascular accident or transient ischemic attack, or seizure disorder in the past year.
- •10.Subject has a history of allergy or hypersensitivity to any of the study drugs
- •11.Subjects with history of connective tissue disorders (eg, lupus, scleroderma, arteritis nodosa).
- •12.Subjects with a history of interstitial lung disease
- •13.Any other malignancy within 5 years prior to enrollment, with the exception of adequately treated in-situ carcinoma of the prostate (Gleason score = 7), cervix, uteri, or nonmelanomatous skin cancer (all treatment of which should have been completed 6 months prior to enrollment).
- •14.Patients has > Grade 1 pre-existing peripheral neuropathy (per CTCAE)
- •15.Subject has serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the subject's safety or the study data integrity.
- •16.Subject is enrolled in any other clinical protocol or investigational trial with an interventional agent or assessments that may interfere with study procedures.
- •17.Subject is unwilling or unable to comply with study procedures
- •18.Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
研究者
相似试验
进行中（未招募）
不适用
A Phase 2 Study to Evaluate the Safety and Efficacy of Weekly Doses of Marqibo® (vincristine sulfate liposomes injection) in Adult Patients with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Adult Patients with Philadelphia Chromosome-negative ALL Who Failed Two Treatment Lines of Anti-leukemia ChemotherapyPhiladelphia Chromosome-negative Acute Lymphoblastic LeukemiaMedDRA version: 9.1Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaEUCTR2006-006978-20-GBHana Biosciences, Inc.56
进行中（未招募）
不适用
A Phase 2 Study to Evaluate the Safety and Efficacy of Weekly Doses of Marqibo® (vincristine sulfate liposomes injection) in Adult Patients with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Adult Patients with Philadelphia Chromosome-negative ALL Who Failed Two Treatment Lines of Anti-leukemia ChemotherapyEUCTR2006-006978-20-DETalon Therapeutics , Inc.65
进行中（未招募）
1 期
A study to evaluate the safety and efficacy of Lerociclib in participants with advanced breast cancerMedDRA version: 20.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10006289Term: Benign and malignant breast neoplasmsSystem Organ Class: 100000004872MedDRA version: 20.0Level: HLTClassification code 10006290Term: Breast and nipple neoplasms malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Metastatic Breast CancerEUCTR2021-005238-40-BEEQRx, Inc.100
进行中（未招募）
1 期
A study to look at how safe and effective glofitamab plus R-CHOP in ctDNA high-risk people with untreated diffuse large B-cell lymphomaCTIS2023-504994-19-00F. Hoffmann-La Roche AG40
进行中（未招募）
2 期
The Safety and Efficacy of THVD-102, a combination of Oxybutynin and Pilocarpine, in Subjects with Primary Focal Hyperhidrosis.ACTRN12615000873527TheraVida, Inc21